Fig. 2

Combined treatment with BRAF and MEK inhibitors suppresses morphologic effects induced by BRAF^V600E in thyrocytes and restores normal follicle structure.

(A) Schematic diagram of experimental scheme and treatment conditions of tg-TOM and tg-BRAF^V600E-TOM larvae. (B) Epifluorescent live images of tg-TOM and tg-BRAF^V600E-TOM larvae treated with either DMSO (vehicle), 2.5 μM dabrafenib, 10 μM selumetinib, or the combination of 2.5 μM dabrafenib and 10 μM selumetinib. (C) Representative confocal images of tg-BRAF^V600E-TOM larvae treated with either DMSO (vehicle), 2.5 μM dabrafenib, 10 μM selumetinib, or the combination of 2.5 μM dabrafenib and 10 μM selumetinib and subject to immunofluorescence (IF) using anti-T4 antibody. (D–E) Quantification of thyroid follicle number (D) and follicle diameter (E) in tg-BRAF^V600E-TOM larvae after drug treatment compared to vehicle (DMSO) control. The experiment was performed in triplicate. *p≤0.05, **p≤0.01, Student's two-tailed t-test, ns: not significant.